FEATURED , Research , Breast Cancer

Alan Stolier, MD/

Carrie Printz on RxPONDER

Carrie Printz

This is an excellent editorial in the journal Cancer by Carrie Printz on the RxPONDER trial, https://www.breastcarenetwork.com/news/results-of-the-rx-ponder-trial,  as well as the SOFT trial (suppression of ovarian function trial) and the TEXT trial (tamoxifen and exemestane trial).  “These trials showed that among premenopausal women with breast cancer, adding ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than treatment with tamoxifen alone. Furthermore, using the aromatase inhibitor exemestane plus ovarian suppression resulted in even higher rates of reduced recurrence”. 

 

Leave A Comment